The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts’ expectations, boosted by revenue from its key drugs.
The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts’ expectations, boosted by revenue from its key drugs.